BLS-M07
/ MOA Life Plus, AnGes MG
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 01, 2023
A double-blind, 4-block randomized, placebo-controlled, adaptive phase 2/3 trial to confirm efficacy and safety of BLS-ILB-E710c in patients with cervical intraepithelial neoplasia 2/3 with extension study
(SGO 2023)
- No abstract available
Clinical • P2/3 data • Gynecology • Oncology
1 to 1
Of
1
Go to page
1